Log in

NASDAQ:IART - Integra Lifesciences Stock Price, Forecast & News

$41.75
+0.98 (+2.40 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$39.06
Now: $41.75
$42.60
50-Day Range
$36.67
MA: $50.59
$61.04
52-Week Range
$34.21
Now: $41.75
$65.09
Volume910,625 shs
Average Volume711,582 shs
Market Capitalization$3.53 billion
P/E Ratio71.98
Dividend YieldN/A
Beta1.09
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, Asia Pacific, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.
Read More
Integra Lifesciences logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IART
CUSIP45798520
Phone609-275-0500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.52 billion
Cash Flow$4.41 per share
Book Value$16.50 per share

Profitability

Net Income$50.20 million

Miscellaneous

Employees4,000
Market Cap$3.53 billion
Next Earnings Date4/22/2020 (Estimated)
OptionableOptionable

Receive IART News and Ratings via Email

Sign-up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter.


Integra Lifesciences (NASDAQ:IART) Frequently Asked Questions

How has Integra Lifesciences' stock been impacted by COVID-19 (Coronavirus)?

Integra Lifesciences' stock was trading at $46.08 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IART shares have decreased by 9.4% and is now trading at $41.75. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Integra Lifesciences?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra Lifesciences in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Integra Lifesciences.

When is Integra Lifesciences' next earnings date?

Integra Lifesciences is scheduled to release its next quarterly earnings announcement on Wednesday, April 22nd 2020. View our earnings forecast for Integra Lifesciences.

How were Integra Lifesciences' earnings last quarter?

Integra Lifesciences Holdings Corp (NASDAQ:IART) issued its quarterly earnings results on Wednesday, February, 19th. The life sciences company reported $0.68 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.01. The life sciences company had revenue of $395.13 million for the quarter, compared to analysts' expectations of $397.51 million. Integra Lifesciences had a return on equity of 16.90% and a net margin of 3.31%. The business's revenue was up 3.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.65 earnings per share. View Integra Lifesciences' earnings history.

When did Integra Lifesciences' stock split? How did Integra Lifesciences' stock split work?

Integra Lifesciences's stock split on the morning of Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly minted shares were payable to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences stock prior to the split would have 200 shares after the split.

What guidance has Integra Lifesciences issued on next quarter's earnings?

Integra Lifesciences updated its FY20 earnings guidance on Wednesday, February, 19th. The company provided earnings per share guidance of $3.00-3.05 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.00. The company issued revenue guidance of $1.55-1.57 billion, compared to the consensus revenue estimate of $1.59 billion.

What price target have analysts set for IART?

9 brokerages have issued 12-month price targets for Integra Lifesciences' shares. Their forecasts range from $56.00 to $75.00. On average, they anticipate Integra Lifesciences' share price to reach $63.90 in the next year. This suggests a possible upside of 53.1% from the stock's current price. View analysts' price targets for Integra Lifesciences.

Has Integra Lifesciences been receiving favorable news coverage?

News articles about IART stock have trended negative recently, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Integra Lifesciences earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned news stories about the life sciences company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the stock's share price in the near term. View the latest news aboutIntegra Lifesciences.

Are investors shorting Integra Lifesciences?

Integra Lifesciences saw a decline in short interest in March. As of March 13th, there was short interest totaling 3,112,400 shares, a decline of 13.3% from the February 27th total of 3,590,000 shares. Based on an average daily trading volume, of 986,300 shares, the days-to-cover ratio is presently 3.2 days. Currently, 4.4% of the shares of the stock are short sold. View Integra Lifesciences' Current Options Chain.

Who are some of Integra Lifesciences' key competitors?

What other stocks do shareholders of Integra Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra Lifesciences investors own include NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Intel (INTC), Activision Blizzard (ATVI), Micron Technology (MU), Netflix (NFLX), salesforce.com (CRM) and Gilead Sciences (GILD).

Who are Integra Lifesciences' key executives?

Integra Lifesciences' management team includes the following people:
  • Mr. Peter J. Arduini, Pres, CEO & Director (Age 54)
  • Dr. Richard E. Caruso Ph.D., Founder and Chairman Emeritus (Age 76)
  • Mr. Glenn G. Coleman, Corp. VP of International & CFO (Age 51)
  • Mr. Daniel L. Reuvers, Corp. VP and Pres of Specialty Surgical Solutions (Age 56)
  • Mr. Robert T. Davis Jr., Corp. VP and Pres of Orthopedics & Tissue Technologies (Age 60)

What is Integra Lifesciences' stock symbol?

Integra Lifesciences trades on the NASDAQ under the ticker symbol "IART."

Who are Integra Lifesciences' major shareholders?

Integra Lifesciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Capital Research Global Investors (10.62%), Champlain Investment Partners LLC (7.07%), Janus Henderson Group PLC (5.02%), State Street Corp (2.11%), Capital International Investors (1.45%) and ArrowMark Colorado Holdings LLC (1.39%). Company insiders that own Integra Lifesciences stock include Barbara B Hill, Christian S Schade, Daniel L Reuvers, Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, John Mooradian, Kenneth Burhop, Lisa Evoli, Peter J Arduini, Raymond G Murphy, Rhonda Germany Ballintyn, Richard E Caruso and Stuart Essig. View institutional ownership trends for Integra Lifesciences.

Which institutional investors are selling Integra Lifesciences stock?

IART stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Capital Bank & Trust Co, Renaissance Technologies LLC, Castleark Management LLC, Capital International Inc. CA, Fort Washington Investment Advisors Inc. OH, Sei Investments Co., and Capital International Investors. Company insiders that have sold Integra Lifesciences company stock in the last year include Christian S Schade, Daniel L Reuvers, Eric Schwartz, Glenn Coleman, John Mooradian, Kenneth Burhop, Lisa Evoli, Peter J Arduini, Raymond G Murphy, and Richard E Caruso. View insider buying and selling activity for Integra Lifesciences.

Which institutional investors are buying Integra Lifesciences stock?

IART stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Norges Bank, Goldman Sachs Group Inc., Champlain Investment Partners LLC, Eaton Vance Management, ArrowMark Colorado Holdings LLC, Mesirow Financial Investment Management Equity Management, and Prudential Financial Inc.. Company insiders that have bought Integra Lifesciences stock in the last two years include Barbara B Hill, and Rhonda Germany Ballintyn. View insider buying and selling activity for Integra Lifesciences.

How do I buy shares of Integra Lifesciences?

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Integra Lifesciences' stock price today?

One share of IART stock can currently be purchased for approximately $41.75.

How big of a company is Integra Lifesciences?

Integra Lifesciences has a market capitalization of $3.53 billion and generates $1.52 billion in revenue each year. The life sciences company earns $50.20 million in net income (profit) each year or $2.74 on an earnings per share basis. Integra Lifesciences employs 4,000 workers across the globe. View additional information about Integra Lifesciences.

What is Integra Lifesciences' official website?

The official website for Integra Lifesciences is http://www.integralife.com/.

How can I contact Integra Lifesciences?

Integra Lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]


MarketBeat Community Rating for Integra Lifesciences (NASDAQ IART)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  398 (Vote Outperform)
Underperform Votes:  482 (Vote Underperform)
Total Votes:  880
MarketBeat's community ratings are surveys of what our community members think about Integra Lifesciences and other stocks. Vote "Outperform" if you believe IART will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IART will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: What is Depreciation?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel